secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001104659-25-032004
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 3.03
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma announces 1-for-20 reverse ADS split to regain Nasdaq compliance
-----------------------------------------------------------------------------

- ADS ratio changed from 1:1 to 1:20 (one ADS now represents 20 ordinary shares) effective April 8, 2025.
- Reverse split automatically converts every 20 existing ADSs into 1 new ADS; ordinary shares unchanged.
- New CUSIP number for ADSs is 74907L409; ticker QNRX remains on Nasdaq Capital Market.
- Objective is to increase ADS per-share price above $1.00 minimum bid to avoid delisting.
- Company cannot guarantee that the ratio change will achieve or sustain Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925032004/0001104659-25-032004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925032004/tm2511401d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-032004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer